Medicenna Therapeutics Corp. (NASDAQ:MDNA) Q1 2023 Earnings Conference Call August 15, 2022 8:30 AM ET
Company Participants
Dan Ferry - IR, LifeSci Advisors
Fahar Merchant - President & CEO
Liz Williams - CFO
Conference Call Participants
Matt Biegler - Oppenheimer
David Martin - Bloom Burton
Catherine Novack - JonesTrading
Arthur He - H.C. Wainwright
Operator
Greetings, and welcome to the Medicenna Therapeutics Corp. First Quarter Fiscal 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Dan Ferry of LifeSci. Thank you. You may proceed.
Dan Ferry
Thank you, operator. And thank you all for participating in today's conference call. This morning, Medicenna issued a press release providing financial results and corporate updates for the quarter-ended June 30, 2022. If you have not yet seen the press release, it is available on the Investors page of Medicenna’s website.
Before we begin, I would like to remind you that certain statements and information shared during this call, constitute forward-looking information within the meaning of applicable securities laws. All statements other than statements of historical facts shared during this call, and that relate to the future operations of the company, and other statements that are not historical facts, including statements related to the clinical potential and development of MDNA11, MDNA55, and the BiSKITs programs, the potential of the Superkine platform, preliminary clinical data, partnering activities, cash runway, the presentation of additional data and other milestones are forward-looking statements that are subject to risks and uncertainties. There could be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ materially from the company's expectations, include the risks detailed in the Annual Information Form, Management's Discussion and Analysis and Form 20-F of the company, and in other filings made by the company with the applicable securities regulators from time-to-time in Canada and the United States.
Listeners are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the company. You are cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect, and actual results may differ materially from those anticipated.